TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

(marketscreener.com) TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer with mutations in BRCA or ATM achieved the primary endpoint of improved radiographic progression-free survival by independent radiology review – Median rPFS of 11....https://www.marketscreener.com/quote/stock/CLOVIS-ONCOLOGY-INC-9500801/news/TRITON3-Phase-3-Trial-of-Rubraca-rucaparib-Achieves-Primary-Endpoint-in-Men-with-Metastatic-Castr-41913696/?utm_medium=RSS&utm_content=20221003